JPS59155310A - 崩壊性の改良された固型薬剤の製造方法 - Google Patents
崩壊性の改良された固型薬剤の製造方法Info
- Publication number
- JPS59155310A JPS59155310A JP2798483A JP2798483A JPS59155310A JP S59155310 A JPS59155310 A JP S59155310A JP 2798483 A JP2798483 A JP 2798483A JP 2798483 A JP2798483 A JP 2798483A JP S59155310 A JPS59155310 A JP S59155310A
- Authority
- JP
- Japan
- Prior art keywords
- degree
- disintegration
- glycolate
- neutralization
- solid preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 17
- 238000006467 substitution reaction Methods 0.000 claims abstract description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 7
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical compound [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000007493 shaping process Methods 0.000 claims description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 17
- 230000008961 swelling Effects 0.000 abstract description 8
- 239000011575 calcium Substances 0.000 abstract description 6
- 229910052791 calcium Inorganic materials 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 description 14
- 229920002678 cellulose Polymers 0.000 description 14
- 235000010980 cellulose Nutrition 0.000 description 14
- 239000007884 disintegrant Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 7
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 5
- 239000007916 tablet composition Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000449 pharmaceutical disintegrant Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- -1 sulfoxymethyl group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2798483A JPS59155310A (ja) | 1983-02-21 | 1983-02-21 | 崩壊性の改良された固型薬剤の製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2798483A JPS59155310A (ja) | 1983-02-21 | 1983-02-21 | 崩壊性の改良された固型薬剤の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59155310A true JPS59155310A (ja) | 1984-09-04 |
| JPH0524139B2 JPH0524139B2 (enrdf_load_stackoverflow) | 1993-04-06 |
Family
ID=12236109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2798483A Granted JPS59155310A (ja) | 1983-02-21 | 1983-02-21 | 崩壊性の改良された固型薬剤の製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59155310A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59167522A (ja) * | 1983-03-14 | 1984-09-21 | Daicel Chem Ind Ltd | 固型薬剤の製造法 |
| JP2003250488A (ja) * | 2002-02-27 | 2003-09-09 | Fancl Corp | 食品組成物及びその製造方法 |
| JP2003250487A (ja) * | 2002-02-27 | 2003-09-09 | Fancl Corp | 粉末含有錠剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5247914A (en) * | 1975-10-11 | 1977-04-16 | Lilly Industries Ltd | Tablet and its prepation |
-
1983
- 1983-02-21 JP JP2798483A patent/JPS59155310A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5247914A (en) * | 1975-10-11 | 1977-04-16 | Lilly Industries Ltd | Tablet and its prepation |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59167522A (ja) * | 1983-03-14 | 1984-09-21 | Daicel Chem Ind Ltd | 固型薬剤の製造法 |
| JP2003250488A (ja) * | 2002-02-27 | 2003-09-09 | Fancl Corp | 食品組成物及びその製造方法 |
| JP2003250487A (ja) * | 2002-02-27 | 2003-09-09 | Fancl Corp | 粉末含有錠剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0524139B2 (enrdf_load_stackoverflow) | 1993-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU628754B2 (en) | Therapeutic agents | |
| Mohanachandran et al. | Superdisintegrants: an overview | |
| US4375468A (en) | Constant order release aspirin composition and method of treating arthritis | |
| US4983398A (en) | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates | |
| CA2301132C (en) | Rapidly disintegrating methylcellulose tablets | |
| JP5723787B2 (ja) | 制御放出の製剤処方または食品処方およびその製造方法 | |
| US5616343A (en) | Cross-linked amylose as a binder/disintegrant in tablets | |
| NO309455B1 (no) | Filmbelagt tablett av paracetamol og domperidon | |
| EP1513504A1 (en) | Sustained release oral dosage forms of gabapentin | |
| JPH06206833A (ja) | 薬剤学的薬剤 | |
| US4601895A (en) | Delayed-action acetylsalicylic acid formulations for oral administration | |
| JP3884056B1 (ja) | 口腔内速崩錠の製造方法 | |
| JP4562797B1 (ja) | 沈降炭酸カルシウムを有効成分とする口腔内崩壊錠 | |
| JPS59155310A (ja) | 崩壊性の改良された固型薬剤の製造方法 | |
| CN101087595A (zh) | 用于缓释药物的片剂 | |
| Wankhede et al. | A Review on Superdisintegrating Agent Used in Pharmaceutical Formulation | |
| JPH10509982A (ja) | 高等植物から獲得できる粉末ヒドロコロイドゴムを利用するｎｓａｉｄの導入 | |
| EP0134289A1 (en) | Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions | |
| AU709413B2 (en) | Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants | |
| Bhowmik et al. | Recent trends in role of superdisintegrants to formulation of solid oral dosage form | |
| JP3967767B1 (ja) | 口腔内速崩錠の製造方法 | |
| JPH0526762B2 (enrdf_load_stackoverflow) | ||
| JPS59176217A (ja) | 固形薬剤用粉粒体組成物 | |
| JPWO2019131411A1 (ja) | 口腔内崩壊錠用エリスリトール顆粒およびその製造方法ならびにそれを用いた口腔内崩壊錠 | |
| Ugoeze et al. | EVALUATION OF A MODIFIED BIOMATERIAL OF TYMPANOTONUS FUSCATA SHELL POWDER II: FORMULATION OF PYRIMETHAMINE AND PYRIDOXINE HYDROCHLORIDE TABLETS |